Con­tro­ver­sial pa­tient deaths in CAR-T study spur a class ac­tion suit against Juno

Juno con­tin­ues to feel the fall­out from its painful, and very brief, tri­al hold for its lead CAR-T JCAR015. In a new­ly filed class ac­tion suit, in­vestors say that they were pur­pose­ful­ly mis­led by Juno ex­ec­u­tives, who kept qui­et about the first sus­pi­cious pa­tient death in May.

Ac­cord­ing to the suit, the com­pa­ny was prompt­ed to tell reg­u­la­tors about the death due to a cere­bral ede­ma. But when it came to its June earn­ings an­nounce­ment, the com­pa­ny stayed silent about any deaths, stick­ing to ev­i­dence of grade 3 neu­ro­tox­i­c­i­ty. And with the com­pa­ny tout­ing its re­sults, CEO Hans Bish­op cashed out of $8.6 mil­lion in shares.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER